Internal Reference Number: FOI_8457
Date Request Received: 12/02/2025 00:00:00
Date Request Replied To: 26/02/2025 00:00:00
This response was sent via: By Email
Request Summary: Usage of high-cost drugs in Ophthalmology
Request Category: Private Individuals
| Question Number 1: I am researching the usage of high-cost drugs in ophthalmology. For the 4 months from September to December 2024, how many unique* patients received the following intra-vitreal treatments for any eye condition:*Please count a patient only once for any treatment, regardless of how many injections or implants they may have received. Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab – Lucentis Ranibizumab Biosimilar | |
| Answer To Question 1: Aflibercept 586 Bevacizumab 6 Brolucizumab 0 Dexamethasone 11 Faricimab 397 Ranibizumab – Lucentis <5 Ranibizumab Biosimilar 0 | |
| Question Number 2: For the patients above, how many were new to intra-vitreal treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments. Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab – Lucentis Ranibizumab Biosimilar | |
| Answer To Question 2: Aflibercept 51 Bevacizumab 5 Brolucizumab 0 Dexamethasone <5 Faricimab 36 Ranibizumab – Lucentis <5 Ranibizumab Biosimilar 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
